NCT06006117 2025-12-19
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
The Lymphoma Academic Research Organisation
Janssen Research & Development, LLC
MEI Pharma, Inc.
SecuraBio
Gilead Sciences